Genprex

Our

Technologies


21st Century Gene Therapies

Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Our teams work closely with world-class researchers, institutions and industry collaborators to expand our pipeline of gene therapies and provide a wider range of novel treatment approaches for patients with cancer and diabetes.

Systemic Gene Therapy Platform for Cancer

Genprex’s oncology drug development program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells. 

REQORSA™ Immunogene Therapy

Our lead product candidate, REQORSA™ immunogene therapy drug (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), uses our unique, proprietary ONCOPREX® nanoparticle delivery system, a systemic gene therapy platform for cancer. The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene. In 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in late-stage NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA in combination with Merck & Co’s Keytruda® (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with Keytruda.

Diabetes Gene Therapy

GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetic patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

Tagrisso® is a registered trademark of AstraZeneca.

Keytruda® is a registered trademark of Merck & Co.